-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on Replimune Group, Raises Price Target to $27

Benzinga·11/16/2026 13:05:53
Listen to the news
Piper Sandler analyst Allison Bratzel maintains Replimune Group (NASDAQ:REPL) with a Overweight and raises the price target from $14 to $27.